Abstract
Anti-inflammatory agents are routinely used to treat inflammatory diseases affecting both anterior and/or posterior segments of the eye. Corticosteroids and NSAIDs can be administered either topically onto the ocular surface structures or injected into the eye. However, one of the most important handicaps of ocular treatments is the presence of several anatomical and physiological barriers in the eye that drastically reduce drug access to the target site. The hydrophobicity of anti-inflammatory agents, low drug bioavailability, and the invasiveness of intraocular drug delivery are main reasons to explore the potential application of drug delivery-related technologies to develop new antiinflammatory ocular therapies. This review summarizes conventional anti-inflammatory treatments for ocular diseases and the ongoing research efforts to develop improved drug delivery systems. Micro-size intraocular implants, microparticles, nanoparticles, and liposomes are the preferred delivery systems in study.
Keywords: Anti-inflammatory drugs, corticosteroids, drug delivery, eye disease, nanomedicine, nanoparticles, NSAIDs, ocular drug administration, Ophthalmology, OCULAR ANTI-INFLAMMATORY THERAPY
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Drug Delivery Systems for Ophthalmic Administration of Antiinflammatory Agents
Volume: 10 Issue: 3
Author(s): Yolanda Diebold, Laura Contreras-Ruiz, Isabel Arranz-Valsero and Laura Garcia-Posadas
Affiliation:
Keywords: Anti-inflammatory drugs, corticosteroids, drug delivery, eye disease, nanomedicine, nanoparticles, NSAIDs, ocular drug administration, Ophthalmology, OCULAR ANTI-INFLAMMATORY THERAPY
Abstract: Anti-inflammatory agents are routinely used to treat inflammatory diseases affecting both anterior and/or posterior segments of the eye. Corticosteroids and NSAIDs can be administered either topically onto the ocular surface structures or injected into the eye. However, one of the most important handicaps of ocular treatments is the presence of several anatomical and physiological barriers in the eye that drastically reduce drug access to the target site. The hydrophobicity of anti-inflammatory agents, low drug bioavailability, and the invasiveness of intraocular drug delivery are main reasons to explore the potential application of drug delivery-related technologies to develop new antiinflammatory ocular therapies. This review summarizes conventional anti-inflammatory treatments for ocular diseases and the ongoing research efforts to develop improved drug delivery systems. Micro-size intraocular implants, microparticles, nanoparticles, and liposomes are the preferred delivery systems in study.
Export Options
About this article
Cite this article as:
Diebold Yolanda, Contreras-Ruiz Laura, Arranz-Valsero Isabel and Garcia-Posadas Laura, Drug Delivery Systems for Ophthalmic Administration of Antiinflammatory Agents, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2011; 10(3) . https://dx.doi.org/10.2174/1871523011109030203
DOI https://dx.doi.org/10.2174/1871523011109030203 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Compromise and Care of the Brains Compartments: The Quintessence of the Neurovascular Unit
Current Neurovascular Research A Contemporary Approach to Macular Edema Treatment in Retinal Vein Occlusion
Vascular Disease Prevention (Discontinued) Down-Regulation of Angiogenic Inhibitors: A Potential Pathogenic Mechanism for Diabetic Complications
Current Diabetes Reviews Subthreshold Diode Micropulse Laser Photocoagulation (SDM) as Invisible Retinal Phototherapy for Diabetic Macular Edema: A Review
Current Diabetes Reviews Measurement and Mapping of Retinal Leakage and Retinal Thickness - Surrogate Outcomes for the Initial Stages of Diabetic Retinopathy
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents The Role of AGEs and AGE Inhibitors in Diabetic Cardiovascular Disease
Current Drug Targets Basic and Clinical Aspects of Gene Therapy for Retinopathy Induced by Diabetes
Current Gene Therapy Diabetes and Vascular Disease: Basic Concepts of Nitric Oxide Physiology, Endothelial Dysfunction, Oxidative Stress and Therapeutic Possibilities
Current Vascular Pharmacology In Situ Gels Based Drug Delivery Systems
Current Drug Therapy Review of and Perspectives on the Toxicology of Graphene-based Materials
Current Drug Metabolism Pharmacogenomics of Open-Angle Glaucoma
Current Pharmacogenomics and Personalized Medicine Fluorescein Fluorescence Use in the Management of Intracranial Neoplastic and Vascular Lesions: A Review and Report of a New Technique
Current Drug Discovery Technologies Angiotensin II, Cell Proliferation and Angiogenesis Regulator: Biologic and Therapeutic Implications in Cancer
Current Vascular Pharmacology The Role of Adipocytokines in Atherogenesis and Atheroprogression
Current Drug Targets Stable Angina Pectoris: Current Medical Treatment
Current Pharmaceutical Design Recent Advances in Management of Diabetic Macular Edema
Current Diabetes Reviews Targeting Plasminogen Activator Inhibitor-1: Role in Cell Signaling and the Biology of Domain-Specific Knock-in Mice
Current Drug Targets Vascular Endothelial Growth Factor (VEGF) Biochemistry and Development of Inhibitory Drugs
Current Drug Therapy Involvement of Orbital Structures in Rheumatic Disease
Current Rheumatology Reviews CD36 as a Therapeutic Target for Endothelial Dysfunction in Stroke
Current Pharmaceutical Design